tert-butyl 9-methyl-3,9-diazabicyclo[4.2.1]nonane-3-carboxylate | 286947-15-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂卓
• 英文名称: tert-butyl 9-methyl-3,9-diazabicyclo[4.2.1]nonane-3-carboxylate
• 英文别名: 9-Methyl-3-tert-butoxycarbonyl-3,9-diazabicyclo-[4.2.1]-nonane
• CAS: 286947-15-7
• 化学式: C₁₃H₂₄N₂O₂
• 分子量: 240.346
• InChiKey: WAKDJTSMKTZWEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl 9-methyl-3,9-diazabicyclo[4.2.1]nonane-3-carboxylate 、 氯甲酸乙酯 以 甲苯 为溶剂， 生成 3-(tert-butyl) 9-ethyl 3,9-diazabicyclo[4.2.1]nonane-3,9-dicarboxylate
  参考文献：
  名称：

  Synthesis and evaluation of ligands for D2-like receptors: The role of common pharmacophoric groups

  摘要：

  Arylcycloalkylamines, such as phenyl piperidines and piperazines and their arylalkyl substituents, constitute pharmacophoric groups exemplified in several antipsychotic agents. A review of previous reports indicates that arylalkyl substituents can improve the potency and selectivity of the binding affinity at D-2-like receptors. In this paper, we explored the contributions of two key pharmacophoric groups, that is, 40-fluorobutyrophenones and 3-methyl-7-azaindoles, to the potency and selectivity of synthesized agents at D-2-like receptors. Preliminary observation of binding affinities indicates that there is little predictability of specific effects of the arylalkyl moieties but the composite structure is responsible for selectivity and potency at these receptors. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2008.12.054
• 作为产物：
  描述：

  二碳酸二叔丁酯 、 9-甲基-3,9-二氮杂双环[4.2.1]壬烷 在 sodium hydroxide 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 tert-butyl 9-methyl-3,9-diazabicyclo[4.2.1]nonane-3-carboxylate
  参考文献：
  名称：

  Heteroaryl diazabicycloalkanes, their preparation and use

  摘要：

  本发明涉及一种新颖的杂环二氮杂双环庚烷衍生物，其通式表示为（I），其任一对映异构体或其混合物，其N-氧化物，其药学上可接受的盐，以标记或非标记形式存在，发现它们在尼古丁乙酰胆碱受体上是胆碱能配体。由于其药理特性，本发明的化合物可能对治疗与中枢神经系统（CNS）的胆碱能系统相关的疾病或紊乱，平滑肌收缩相关的疾病或紊乱，内分泌疾病或紊乱，神经退行性疾病或紊乱，炎症相关的疾病或紊乱，疼痛以及因滥用化学物质而导致的戒断症状等各种疾病或紊乱可能有用。

  公开号：

  US20020037893A1

文献信息

• Heteroaryl diazabicycloalkanes, their preparation and use
  申请人：——

  公开号：US20020037893A1

  公开（公告）日：2002-03-28

  The present invention relates to novel heteroaryl diazabicycloalkane derivatives represented by general formula (I), any of its enantiomers or any mixture thereof, an N oxide thereof, a pharmaceutically acceptable salt thereof, in a labelled or un-labelled form, which are found to be cholinergic ligands at the nicotinic Acetyl Choline Receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neurodegeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  本发明涉及一种新颖的杂环二氮杂双环庚烷衍生物，其通式表示为（I），其任一对映异构体或其混合物，其N-氧化物，其药学上可接受的盐，以标记或非标记形式存在，发现它们在尼古丁乙酰胆碱受体上是胆碱能配体。由于其药理特性，本发明的化合物可能对治疗与中枢神经系统（CNS）的胆碱能系统相关的疾病或紊乱，平滑肌收缩相关的疾病或紊乱，内分泌疾病或紊乱，神经退行性疾病或紊乱，炎症相关的疾病或紊乱，疼痛以及因滥用化学物质而导致的戒断症状等各种疾病或紊乱可能有用。
• Diazabicyclic CNS active agents
  申请人：——

  公开号：US20030225268A1

  公开（公告）日：2003-12-04

  Compounds of formula I: 1 or pharmaceutically acceptable salts thereof, are useful for controlling synaptic transmission in mammals.

  式I：1的化合物或其药学上可接受的盐，用于控制哺乳动物的突触传递。
• Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
  申请人：ABBOTT LABORATORIES

  公开号：EP1359152A2

  公开（公告）日：2003-11-05

  Compounds of formula (I) or a pharmaceutically acceptable salt thereof wherein: V is selected from the group consisting of a covalent bond and CH2; W is selected from the group consisting of a covalent bond, CH2 and CH2CH2; X is selected from the group consisting of a covalent bond and CH2; Y is selected from the group consisting of a covalent bond, CH2 and CH2CH2; Z is selected from the group consisting of CH2 and CH2CH2, and CH2CH2CH2; L1 is selected from the group consisting of a covalent bond and (CH2)n; n is 1-5; R1 is selected from the group consisting of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), and (l); R2 is selected from the group consisting of hydrogen, alkoxycarbonyl, alkyl, aminoalkyl, aminocarbonylalkyl, benzyloxycarbonyl, cyanoalkyl, dihydro-3-pyridinylcarbonyl, hydroxy, hydroxyalkyl, phenoxycarbonyl, and -NH2; are useful for controlling synaptic transmission in mammal.

  式(I)化合物或其药学上可接受的盐 其中 V 选自由共价键和 CH2 组成的组； W 选自由共价键、CH2 和 CH2CH2 组成的组； X 选自由共价键和 CH2 组成的组； Y 选自由共价键、CH2 和 CH2CH2 组成的组； Z 选自 CH2 和 CH2CH2 及 CH2CH2CH2 组成的组； L1 选自由共价键和 (CH2)n 组成的组； n 为 1-5； R1 选自由(a)、(b)、(c)、(d)、(e)、(f)、(g)、(h)、(i)、(j)、(k)和(l)组成的组； R2 选自氢、烷氧羰基、烷基、氨基烷基、氨基羰基烷基、苄氧羰基、氰基烷基、二氢-3-吡啶基羰基、羟基、羟基烷基、苯氧羰基和-NH2 所组成的组； 可用于控制哺乳动物的突触传递。
• DIAZABICYCLIC DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
  申请人：ABBOTT LABORATORIES

  公开号：EP1147112B1

  公开（公告）日：2003-10-29
• HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE
  申请人：NEUROSEARCH A/S

  公开号：EP1177196B1

  公开（公告）日：2004-03-10